Literature DB >> 16249052

Duration of HPV-associated risk for high-grade cervical intraepithelial neoplasia.

Zoltán Hernádi1, László Gazdag, Krisztina Szoke, Tamás Sápy, Zoárd T Krasznai, József Kónya.   

Abstract

OBJECTIVE: To evaluate the duration of high-risk HPV-associated cancer risk. STUDY
DESIGN: Patients who had had a routine diagnostic Hybrid Capture Tube Test (HCT) due to squamous cell abnormalities of the uterine cervix were followed-up until the endpoint of histologically diagnosed cervical intraepithelial neoplasia (CIN).
RESULTS: Six hundred and thirty-eight women were followed during a cumulative follow-up of 16,423 patient months. The adjusted relative risk associated with the positive HR-HCT test for high-grade CIN/52.0 (20.9-19.2)/ proved to be higher than that of the cytological atypia/5.44 (2.52-11.77)/. At the end of the 30 months of follow-up the crude and adjusted risks for CIN2+ were 214.3 (28.4-1615.7) and 196.7 (25.4-1525.2), respectively in the HPV 16/18 group, and after 30 months, the crude and adjusted RR decreased to 57.6 (10.4-318.9) and 29.2 (5.02-170.0). In the groups of other high-risk types and possibly high-risk types the general tendency was the same. However, new CIN2+ cases were not detected after the 30th month of follow-up in these later groups.
CONCLUSIONS: HPV16/18 associated relative risk is nearly 200 times higher than that of the HPV negative population and an outstanding risk persists with duration of about 30 months. The risk is manifested in progression to high-grade CIN lesions mainly within a 2 years interval after the first detection of HPV 16/18 infection.

Entities:  

Mesh:

Year:  2005        PMID: 16249052     DOI: 10.1016/j.ejogrb.2005.08.005

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  5 in total

Review 1.  Human papillomavirus type 16 E5 protein as a therapeutic target.

Authors:  Sang-Woo Kim; Joo-Sung Yang
Journal:  Yonsei Med J       Date:  2006-02-28       Impact factor: 2.759

2.  CpG methylation in human papillomavirus (HPV) type 31 long control region (LCR) in cervical infections associated with cytological abnormalities.

Authors:  Brigitta László; Annamária Ferenczi; László Madar; Eszter Gyöngyösi; Anita Szalmás; Levente Szakács; György Veress; József Kónya
Journal:  Virus Genes       Date:  2016-04-20       Impact factor: 2.332

3.  Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review).

Authors:  José Veríssimo Fernandes; Thales Allyrio Araújo DE Medeiros Fernandes; Jenner Chrystian Veríssimo DE Azevedo; Ricardo Ney Oliveira Cobucci; Maria Goretti Freire DE Carvalho; Vania Sousa Andrade; Josélio Maria Galvão DE Araújo
Journal:  Oncol Lett       Date:  2015-01-16       Impact factor: 2.967

4.  Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis.

Authors:  Yulan Gu; Chuandan Wan; Jiaming Qiu; Yanhong Cui; Tingwang Jiang; Zhixiang Zhuang
Journal:  PLoS One       Date:  2020-02-06       Impact factor: 3.240

5.  Cytological and histopathological aspects concerning preinvasive squamous cervical lesions.

Authors:  Mihaela Muntean; Cristiana Simionescu; Rodica Taslîcă; Corina Gruia; A Comanescu; Nicoleta Pătrană; Georgiana Fota
Journal:  Curr Health Sci J       Date:  2010-03-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.